Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study.
Riedl MA, Aygören-Pürsün E, Baker J, Farkas H, Anderson J, Bernstein JA, Bouillet L, Busse P, Manning M, Magerl M, Gompels M, Huissoon AP, Longhurst H, Lumry W, Ritchie B, Shapiro R, Soteres D, Banerji A, Cancian M, Johnston DT, Craig TJ, Launay D, Li HH, Liebhaber M, Nickel T, Offenberger J, Rae W, Schrijvers R, Triggiani M, Wedner HJ, Dobo S, Cornpropst M, Clemons D, Fang L, Collis P, Sheridan WP, Maurer M.
Riedl MA, et al.
Allergy. 2018 Sep;73(9):1871-1880. doi: 10.1111/all.13466. Epub 2018 Jun 17.
Allergy. 2018.
PMID: 29688579
Free PMC article.
Clinical Trial.